Safety and Immunogenicity of EBA-175 RII-NG Malaria Vaccine Administered Intramuscularly
Status:
Completed
Trial end date:
2008-04-01
Target enrollment:
Participant gender:
Summary
Malaria is an illness caused by a parasite (an animal or plant that lives in or on a host)
that enters the human body through the bite of an infected mosquito. The purpose of this
study is to find out about the safety of an experimental malaria vaccine and whether the
vaccine causes humans to produce antibodies (proteins made by the body's immune system to
help control or prevent infection). Four strengths of the vaccine will be tested. The lowest
strength of the vaccine will be tested before the next higher strength is tested. Each dosage
(shot) of vaccine will be given to 18 people in 4 dosage groups on Day 0, at 1 month and at 6
months. Two people in each dosage group will receive injections of a placebo (contains no
medication). Participants will include 80 healthy adults between 18 and 40 years of age.
Multiple blood draws will occur over the duration of the study. Participants will be involved
in study related procedures for approximately 13 months.
Phase:
Phase 1
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)